Cavion, Inc., a leading clinical stage biotechnology company committed to developing novel therapeutics for people with neurological diseases, today announced promising results of the T-CALM Phase 2 clinical trial of its first-in-class T-type calcium channel modulator CX-8998 in essential tremor. The company plans to present results from this proof-of-concept study as a late-breaking poster on Monday, October 8 at the International Congress of Parkinson’s Disease and Movement Disorders® in Hong Kong.
Multiple secondary and exploratory endpoints collectively showed that treatment with CX-8998 10mg twice daily resulted in statistically significant improvement versus placebo in activities of daily living and patient-reported and clinical outcome measures, despite the study’s primary endpoint being missed. In the study, CX-8998 demonstrated a favorable safety and tolerability profile, with patients in the drug treatment arm reporting higher levels of satisfaction with tremor control medication compared to patients on placebo.
“After decades without new effective drug therapy options, we believe that the neurostabilizing effects of CX-8998 provide hope for essential tremor patients,” said Spyros Papapetropoulos, MD, PhD, Cavion’s Executive Vice President of Research & Development and Chief Medical Officer. “The data are particularly compelling given that about two-thirds of patients in the study were on standard of care treatment and significant improvement was achieved with CX-8998 on several measures in a study lasting just one month.”
“Essential tremor is a challenge to treat, and patients often do not respond favorably to the existing medications, many of which have been available for decades,” said Karl Kieburtz, MD, MPH, Professor of Neurology at the University of Rochester Medical Center. “Cavion’s CX-8998 has a novel mechanism of action that may provide substantive improvement, and it could be an important therapeutic contribution above and beyond what we currently have for essential tremor. I look forward to its clinical progress and further investigation. Better medications are needed to treat this common and disabling movement disorder.”
T-CALM was a 28-day, double-blind, placebo-controlled Phase 2 proof-of-concept clinical trial in 95 patients with moderate to severe essential tremor, conducted at 25 sites across the United States. Patients were randomized to receive either placebo or CX-8998 titrated up to 10mg dosed twice daily (BID). A majority of subjects (64 percent) added study drug to their existing standard of care anti-tremor medication.
The primary study endpoint using remote video rating of the Tremor Research Group Essential Tremor Rating Assessment Scale – Performance Subscale (TETRAS-PS), a measure of tremor severity, did not meet significance at Day 28 (p=0.696). In contrast, the same TETRAS-PS scale rated by the study investigators who observed the patients in person resulted in a significant improvement in tremor severity at Day 28 for the CX-8998 treated group compared to placebo (p=0.027). Independent analysis of the video rating process uncovered unexpected complications in implementation. Cavion is working closely with the scientific community to enhance central video rating for use in interventional studies.
Multiple secondary and exploratory endpoints collectively showed statistical significance, with benefits after 28 days of treatment in patients receiving CX-8998 10mg twice daily (BID) compared to placebo in the following scales:
- The TETRAS Activities of Daily Living (TETRAS-ADL) scale, a measure of tremor impact on daily activities (p=0.049)
- The Clinician Global Impression of Improvement (CGI-I), a measurement of physician-reported global improvement (p=0.001)
- The TETRAS Total Score (TETRAS ADL + TETRAS-PS rated by the study Investigators, p=0.029)
- The Goal Attainment Scale (GAS), a measure of progress toward patient-selected goals (such as dressing oneself, writing a sentence, or drinking out of a cup) (p=0.034)
In addition, the Patient Global Impression of Change (PGI-C), a measure of patient-reported improvement, trended towards significance favoring CX-8998 (p=0.089). Kinesia One, an algorithm-based digital measure developed for Parkinson’s disease, failed to detect a treatment difference in Essential Tremor patients. Additional analyses, including patient satisfaction with control by anti-tremor medication and traditional and digital spirography, support a treatment benefit with CX-8998. The drug showed a favorable safety and tolerability profile, with the majority of adverse events mild to moderate, transient and non-recurring. No major differences between CX-8998 and placebo were observed in laboratory values, vital signs or electrocardiography.
In addition to the T-CALM study for essential tremor, CX-8998 is currently being studied in T-WAVE, a multi-center Phase 2 clinical trial for generalized epilepsy with absence seizures. “The body of evidence supporting our ground-breaking approach is rapidly expanding,” said Andrew Krouse, President and CEO of Cavion. “Our pipeline of T-type calcium channel therapies extends beyond tremor to other neurological diseases that share a common pathophysiology. We look forward to initiating a Phase 3 study in tremor soon.”